Categories
Editorial

Aether Industries Ltd IPO: All You Need to Know

The IPO ‘may-hem’ continues in the Indian stock markets! Gujarat-based speciality chemical manufacturer Aether Industries Ltd has launched its three-day initial public offering (IPO) today— May 24. In this article, we analyse the company and its IPO. 

Company Profile – Aether Industries Ltd

Established in 2013, Aether Industries Ltd (AIL) is one of the fastest-growing speciality chemical manufacturing companies in India. It produces advanced intermediates and chemicals involving complex, differentiated chemistry and technology core competencies. They started building an in-house research & development (R&D) team in 2013 and commenced commercial operations in FY17. 

The company operates through three business models:

  1. Large-scale manufacturing of its own intermediates and speciality chemicals.
  2. Contract research and manufacturing services.
  3. Exclusive manufacturing

AIL’s portfolio consisted of over 25 chemical products as of March 31, 2022. Their key customers are based in North America, Europe, and India. Prominent clients include Adama Ltd (Israel), BYK Group (Germany), UPL Limited, Divi’s Labs, and Dr. Reddy’s Labs. The company derives 62.6% of its revenue from the pharma segment and 22.9% from the agrochemical segment. Exports make up ~49% of its total revenue, which also acts as a natural hedge against volatility in raw materials sourced from overseas. It owns and operates two manufacturing facilities in Surat, Gujarat.

Aether Industries grew at an annualized rate (CAGR) of 49.5% between 2019 and 2021. The company’s vision is to create a niche in the global chemical industry with a creative approach to chemistry and technology systems. 

About the IPO

Aether Industries Ltd’s public issue opens on May 24 and closes on May 26. The company has fixed Rs 610-642 per share as the price band for the IPO.

The fresh issue of shares (of the face value of Rs 10 each) aggregates to Rs 627 crore. The IPO also includes an offer for sale (OFS) by promoters and early investors, aggregating to Rs 181.04 crore. Individual investors can bid for a minimum of 23 equity shares (1 lot) and in multiples of 23 shares thereafter. You will need a minimum of Rs 14,766 (at the cut-off price) to apply for this IPO. The maximum number of shares that a retail investor can apply is 299 equity shares (13 lots).

The company will utilise the net proceeds from the IPO for the following purposes:

  • Repayment/prepayment of borrowings – Rs 138 crore
  • Funding capital expenditure requirements (greenfield project in Surat) – Rs 163 crore
  • Funding working capital requirements – Rs 165 crore
  • General corporate purposes.

The total promoter holding in Aether Industries will decline from 96.96% to 87.09% post the IPO.

Financial Performance

AIL has posted a consistent increase in total revenue and profits over three financial years (FY19-21). The three part-business model works in perfect synergy. Its revenue from exports increased at a CAGR of 58.5% from Rs 100.09 crore in FY19 to Rs 251.6 crore in FY21.

The company reported a 32.5% YoY increase in revenue from operations to Rs 442.5 crore during the 9 months ended December 2021 (9M FY22). Net profit rose 72.7% YoY to Rs 82.9 crore during the same period. EBITDA stood at Rs 126 crore, up 64% YoY.

Risk Factors

  • Aether Industries faces various risks associated with operations involving the manufacture, usage, and storage of hazardous substances.
  • The company derives ~73% of its total revenue from top 20 customers (as of Dec 31, 2021). Its operations will be adversely affected if these customers choose not to source their requirements from AIL or if they terminate long-term contracts.
  • Non-compliance with safety, health, and environmental laws will severely harm AIL’s business.
  • The company does not have long-term agreements with suppliers of raw materials. A surge in the cost of raw materials or any shortfall in supply could adversely impact its overall operations.
  • All of AIL’s manufacturing facilities are located in Gujarat, exposing them to regulatory or geography-specific risks.

IPO Details in a Nutshell

The book-running lead managers to the public issue are HDFC Bank and Kotak Mahindra Capital. AIL filed the Red Herring Prospectus (RHP) for its IPO on May 16. You can read it here. Out of the total offer, 50% is reserved for Qualified Institutional Buyers (QIBs), 15% for Non-Institutional Investors (NIIs), and 35% for retail investors.

Ahead of the IPO, AIL raised Rs 240 crore from anchor investors.

Conclusion

The chemical industry is one of the most vital and fastest-growing industries in our country. Numerous companies thrive in this sector, which makes it highly competitive. They have flourished mainly due to the surge in demand from the agricultural, pharmaceutical, material science, and paint industries. As per a report from India Brand Equity Foundation (IBEF), the specialty chemicals sector is expected to grow at an annual growth rate of 12.4% to $64 billion within the next three years. The strong R&D capabilities and differentiated portfolio of products will help Aether Industries effectively compete in this sector.

AIL will be competing with leading players like Clean Science & Technology Ltd, Navin Fluorine International, Vinati Organics, PI Industries, and Fine Organics Ltd once it gets listed. You can read our in-depth analysis of India’s chemical industry here.

AIL’s IPO shares are trading at a premium of Rs 4 in the grey market. Before applying to this IPO, we will wait to see if the portion reserved for institutional investors gets oversubscribed. Do consider the risks associated with the company and come to your own conclusion.

What are your views on Aether Industries Ltd’s IPO? Will you be applying for it? Let us know in the comments section of the marketfeed app!

Categories
Editorial

Grasim Industries: A Jack Of All Trades

Aditya Birla Grasim, popularly known as GRASIM is an Indian company that manufactures textile, cement, sponge iron, chemicals and even runs an Asset Management Company on the side! A flagship of the well-known Aditya Birla Group with its many subsidiaries, the company is a buzz on Dalal Street. The company’s profitable Q4FY21 results did boost its share price. The company has recorded some really good profits for the last two quarters. We shall analyze how the company runs, how good or bad is its financials, and what lies ahead of it. 

Grasim: The Business

  • The company has a fair share of unrelated and diversified businesses in its briefcase. They are:
    • Textile, Viscose Staple Fibre
    • Cement
    • Chemicals
    • Financial Services
    • Others
  • Grasim initially started as simply a textile business. It imported Viscose Staple Fibre (VSF)/Viscose popularly known as ‘Rayon’ and used it to manufacture garments. The company later started manufacturing VSF domestically. The company is now the largest VSF manufacturer in India. Its textile business has grown into over 30 major brands and a VSF manufacturing capacity of 578 kilotonnes per annum (KTPA).
  • Speaking of the segment that contributes the most (54%) to the revenue, the cement business. Grasim already had a thriving cement business, Samruddhi Cement Limited (SCL). In 2004, the company gained a controlling stake in UltraTech Cement. It kept on increasing its stake in UltraTech Cement over the years and then merged Samruddhi Cement with UltraTech. Ultratech Cement is listed on NSE and has delivered good profit growth of 18.59% CAGR over the last 5 years.
  • Speaking of its chemical business, Grasim manufactures chemicals used for various industrial applications. Furthermore, It has two sub-segments –
    • Chlor-Alkali– Used to manufacture chlorine-based chemicals used for different industrial processes. Production of Caustic Soda is a major contributor to the Chemicals segment.
    • Epoxy– Used to make plastics paints, adhesives, coatings, primers, sealers, and other such materials.
  • Aditya Birla Capital is the holding company of all financial services on behalf of Grasim. It offers just about any and every kind of service that a financial services company can offer. In the insurance business, it offers life insurance, health insurance, motor insurance, corporate general insurance, The Aditya Birla Asset Management Company, the mutual fund business also falls under it. To know more about the services offered by Aditya Birla Capital, click Here
  • The company had a fairly successful fertilizer business named Info-Gulf Fertilizers (IGF). The company sold its fertilizer business to Singapore-based Indorama Corp’s Indian entity for a cash consideration of Rs 2,649 crore. The divestment is expected to be completed by Q2FY22.

Finances 

.Q4FY21Q3FY21Q4FY19
Revenue24,529.521,341.120,174.6
Profit/Loss1,715.51,388.81,505.9
Consolidated Performance Statement(All Amounts in Rs Crore)
  • If we take a look at the visual representation given above we understand that even though the company’s revenue has increased massively, it has performed rather poorly on its expenditure which happens to eat into its profits. 
  • Grasim’s debt management isn’t too impressive either. The company has loaded itself with debt as it expanded its operations. It has long-term borrowings of Rs 58,745.9 crores for some of its VSF, Cement, and Chemical segment projects. The company has short-term debt of Rs 11,988.1 crore. Its Debt/Equity ratio has also increased considerably due to the heavy debt burden.
  • The company is growing inorganically. The diversification is a good thing but Grasim doesn’t seem to manage it in a proper way. The company’s profit margins have been showing decreasing profitability. The second wave of COVID-19 will impact profitability with decreased production volumes, a disrupted supply chain, and reduced demand.  
  • Coming to liquidity and insolvency, the company’s cash position isn’t bright considering the amount of debt burden that the company has. The current ratio and quick ratio are two important indicators of a company’s liquidity. These two metrics for the companies have deteriorated over the past.
  • The company has witnessed an increasing FII and Promotor shareholding over the past few years. This is seen as a positive sign by investors since a promotor would have its personal interest vested in the company and might also believe that the company is undervalued. Other Birla Group companies like HINDALCO and Birla Group Holdings Pvt Ltd. also own a stake in Grasim.
  • Despite the negative outlook towards the financial performance of the company, one shouldn’t forget that UltraTech Cement, one of Grasim’s subsidiaries posted a profit while the country was still ravaged by the first wave of COVID-19. It did so by cutting costs and “efficiently” managing its inventory and projects. Things could always change for a company with a legacy like Grasim. 
  • Over the past 1 year, Grasim has returned ~154% and more than 67% in the past 6 months on investors’ money. The company has such returns amidst a lockdown despite being a ‘large-cap’ company that tends to move about in a consolidated manner. 

What Lies Ahead

The Q4FY21 reports of Grasim show that the company’s revenue was up by 19.42% while its net profit grew by 33.62%. The company’s operating expenses for the quarter also grew by 20% (QoQ). These profits were supported by a surge in international prices of VSF, especially in China. China also happens to be the largest producer of VSF. One should note that the international markets are recovering faster than the domestic markets and Grasim continues to increase its exports. This could be a silver lining in turbulent times. 

From the earnings call of Grasim for Q4FY21, we get to know the following about Grasim’s plan for Capital Expenditure (CAPEX) for FY22. The total CAPEX spent for FY21 stood at Rs.1,508 crores.

  • Grasim plans to spend The CAPEX plan for FY22 excluding paints and fertilizer is Rs.2,604 crores 
  • The company plans to expand VSF capacity at the existing VIlayat Plant in Gujarat.
  •  It plans to expand its epoxy production capacity by 125,000 tons. 
  • In the Chlor-Alkali business, Grasim plans investment in a ~200TPD Caustic brownfield expansion at Vilayat, Gujarat.

Grasim faces what is called the ‘Conglomerate Discount’. A conglomerate is a company that owns a stake in smaller companies that are diversified. A diversified company could face two of the potential outcomes. Firstly, it could mitigate risk by diversifying its business. Second, it could so happen that its loss-making businesses could eat into the consolidated profit. Essentially, we are talking of over-diversification over here. While things seem bright before the second wave of coronavirus and dull after it struck, the story seems no different for Grasim.

The company is focusing on vaccinating its employees to ensure smooth operations in business. If the company alters its expenses, manages to hike exports, and improve efficiency, one can expect something good on the way for its investors.

Categories
Market News

Rossari Biotech IPO – What’s in Store?

About Rossari Biotech.

Rossari Biotech is a one of the leading speciality chemical manufacturing companies in India. They provide customized solutions to specific industrial and production requirements. The company specializes in the following:

  • Home, Personal Care and Performance Chemicals
  • Textile speciality chemicals.
  • Animal health and nutrition products

They manufacture most of their products from their manufacturing facility in Dadra and Nagar Haveli with a presence in about 17 countries. Currently, their production capacity is 100,000 MTPA(Million Tonnes Per Annum). Moreover, It has two R&D facilities one in IIT Bombay and an inhouse one in Silvassa.

About the IPO

Rossari Biotech filed a DHRP (Draft Red Herring Prospectus) for an IPO initially estimated at Rs. 700 crores in mid-December. However, the IPO was later pegged at Rs. 500 crores considering global slowdown due to coronavirus pandemic.

The subscription period set was between 13th July 2020 and 15 July 2020. By end of the subscription period, Rossari Biotech was subscribed 79 times (i.e. demand for the share was 79x in the market than the prescribed value). The issue price is set between Rs. 423-Rs. 425 with the ticker hitting the market on 23rd July. The IPO managed to issue a total of 11,682,033 shares. Additionally, The IPO managed to raise 496 Crs.

To have a look at the Rossari Biotech’s Annual Reports. Click Here.